Skip to content


BMC Bioinformatics

Open Access

Genomic analysis of a rare human tumor

  • Steven JM Jones1Email author,
  • Janessa Laskin2,
  • Yvonne Y Li1,
  • Obi L Griffith1,
  • Jianghong An1,
  • Mikhail Bilenky1,
  • Yaron S Butterfield1,
  • Timothee Cezard1,
  • Eric Chuah1,
  • Richard Corbett1,
  • Anthony Fejes1,
  • Malachi Griffith1,
  • John Yee3,
  • Montgomery Martin2,
  • Michael Mayo1,
  • Nataliya Melnyk4,
  • Ryan D Morin1,
  • Trevor J Pugh1,
  • Tesa Severson1,
  • Sohrab P Shah4, 5,
  • Margaret Sutcliffe2,
  • Angela Tam1,
  • Jefferson Terry4,
  • Nina Thiessen1,
  • Thomas Thomson2,
  • Richard Varhol1,
  • Thomas Zeng1,
  • Yongjun Zhao1,
  • Richard A Moore1,
  • David G Huntsman3,
  • Inanc Birol1,
  • Martin Hirst1,
  • Robert A Holt1 and
  • Marco A Marra1
BMC Bioinformatics201011(Suppl 4):O3

Published: 23 July 2010


SorafenibSunitinibSulindacCopy Number GainOncogenic Mechanism


The introduction of next-generation DNA sequencing devices into the field of oncology provides an unprecedented mechanism to determine the underlying genetic changes that have occurred within a tumor and also the changes that accrue during treatment. An enhanced understanding of the oncogenic mechanisms could have an immediate clinical role in the treatment of rare tumors - where treatment protocols do not exist and their rarity would indicate that clinical trials would be unlikely to be undertaken for their establishment.


We have investigated the utility of massively parallel sequencing to characterize a rare adenocarcinoma of the tongue, before and after treatment. In the pre-treatment tumor we identified 7,629 genes within regions of copy number gain, 1,078 genes exhibited increased expression relative to the blood and unrelated tumors and four genes contained somatic protein-coding mutations. Our analysis suggested the tumor cells were driven by the RET oncogene and its other pathway constituents. Genes whose protein products are targeted by the RET inhibitors sunitinib and sorafenib correlated with being amplified and or highly expressed. Consistent with our observations subsequent administration of sunitinib was associated with stable disease lasting 4 months, after which the lung lesions began to grow. Administration of sorafenib and sulindac provided disease stabilization for an additional 3 months after which the cancer progressed and new lesions appeared. A metastasis recurring in the skin was determined to possess 7,288 genes within copy number amplicons, 385 genes exhibiting increased expression relative to other tumours and 9 new somatic protein coding mutations. The observed mutations and amplifications were found to be consistent with resistance to therapy arising through further activation of RET pathway and nascent activation of the AKT pathway.


Our results provide evidence for the clinical utility of complete genomic characterization and direct in-vivo genome-wide characterization of the mutations accruing within a tumor under drug selection.

Authors’ Affiliations

Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, Canada
British Columbia Cancer Agency, Vancouver, Canada
Vancouver General Hospital, Vancouver, Canada
Centre for Translational and Applied Genomics of British Columbia Cancer Agency and the Provincial Health Services Authority Laboratories, Vancouver, Canada
Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, Canada


© Jones et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.